Skip to main content
Fig. 2 | BMC Rheumatology

Fig. 2

From: Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

Fig. 2

Time to achieve individual MDA domain criteria among guselkumab-randomized patients using scores deriving from native scales (a) and scores deriving from normalized scales (b). HAQ-DI = Health Assessment Questionnaire-Disability Index; LEI = Leeds enthesitis index; MDA = minimal disease activity; PASI = Psoriasis Area Severity Index; SJC = swollen joint count; TJC = tender joint count

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us